RXi Presents Proof-of-Concept Data for Anti-Scarring, Retinal Programs

At an investor conference this week, the company demonstrated in vivo data showing "robust" uptake of its self-delivering rxRNAs, and successful dose-dependent silencing of target molecules in rodent models.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.